SpringWorks Therapeutics, Inc.

Overview

• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersStamford, Connecticut¹
• Incorporated inDE²
• Business address100 Washington Boulevard, Stamford, Ct 06902²
• Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

We are a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. We have a differentiated portfolio of small molecule targeted oncology assets, including two approved products and several clinical and preclinical candidates at various stages of development, and are advancing programs in rare tumor types as well as highly prevalent, genetically defined cancers. Our strategic approach and operational excellence across research, translational science, and clinical development have enabled us to successfully launch two products, investigate additional product candidates across various clinical trials, and enter into multiple shared-value partnerships with industry leaders to expand our portfolio. From this foundation, we …³ From its latest annual report

Corporate structure

SpringWorks Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SpringWorks Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our headquarters are located in Stamford, Connecticut, where we have leased approximately 24,000 square feet of office space under a lease that expires in April 2028, with two five-year renewal options or one ten-year renewal option. Various corporate functions including clinical development operations, our discovery lab and translational operations are based in Research Triangle Park in Durham, North Carolina, where we have leased approximately 22,352 square feet of office space under a lease that expires in 2029, with two five-year renewal options. We believe that our current and planned facilities are adequate to meet our needs for the foreseeable future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations.

Item 2 of the 10-K filed Feb 20, 2025.³

Leadership

Who has led SpringWorks Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerSaqib Islam Sep 12, 2019 to now¹³
• Chief financial officerPerier I. Francis Jr. Sep 12, 2019 to now¹⁴
• Chief operating officerBadreddin Edris Jan 11, 2021 to now¹⁵

Timeline

1. Jul 1, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights³³
2. Jun 26, 20258-K Shareholder vote³⁴
3. Jun 16, 20258-K Other events³⁵
4. May 14, 20258-K Shareholder vote³⁶
5. Apr 28, 20258-K Entered a material agreement; Regulation FD disclosure³⁷
6. Feb 20, 20258-K Results of operations³⁸
7. Feb 12, 20258-K Regulation FD disclosure; Other events³⁹
8. Jan 13, 20258-K Results of operations; Regulation FD disclosure⁴⁰
9. Nov 12, 20248-K Results of operations⁴¹
10. Aug 7, 20248-K Results of operations⁴²
11. Jul 30, 20248-K Executive or director change⁴³
12. Jun 7, 20248-K Ended a material agreement⁴⁴
13. Sep 12, 2019New chief executive Saqib Islam becomes CEO¹³

Calendar

When it reported results

1. Feb 20, 2025Reported quarterly or annual results³⁸
2. Jan 13, 2025Reported quarterly or annual results⁴⁰
3. Nov 12, 2024Reported quarterly or annual results⁴¹
4. Aug 7, 2024Reported quarterly or annual results⁴²
5. May 2, 2024Reported quarterly or annual results⁴⁵
6. Feb 27, 2024Reported quarterly or annual results⁴⁶
7. Nov 2, 2023Reported quarterly or annual results⁴⁷
8. Aug 2, 2023Reported quarterly or annual results⁴⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

302 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 42 major events, 159 insider forms, 30 large holders, 56 other. The latest 20:

1. Nov 12, 2025SCHEDULE 13G/A EDGAR
2. Aug 8, 2025SCHEDULE 13G EDGAR
3. Jul 11, 202515-12G EDGAR
4. Jul 7, 2025SCHEDULE 13G EDGAR
5. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
6. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
7. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
8. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
9. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
10. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
11. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
12. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
13. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
14. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
15. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
16. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
17. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
18. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
19. Jul 2, 20254 OWNERSHIP DOCUMENT EDGAR
20. Jul 1, 2025S-8 POS EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

35 open-market trades by officers, directors and large owners since October 2021: 0 buys and 35 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Goldman SachsSCHEDULE 13G/A, 1 filing Nov 12, 2025⁴⁹
• Hudson Bay Capital Management LPSCHEDULE 13G, 1 filing Aug 8, 2025⁵⁰
• GLAZER CAPITAL, LLCSCHEDULE 13G, 1 filing Jul 7, 2025⁵¹
• FMR LLCSCHEDULE 13G/A, 5 filings Feb 9, 2022 to May 7, 2025⁵²
• Deep Track Capital, LPSCHEDULE 13G/A, 3 filings Apr 14, 2023 to Feb 14, 2025⁵³
• VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Jan 31, 2025⁵⁴
• Boxer Capital Management, LLCSC 13G/A, 1 filing Oct 25, 2024⁵⁵
• EcoR1 Capital, LLCSC 13G/A, 2 filings Sep 16, 2022 to Feb 14, 2024⁵⁶
• State Street CorporationSC 13G/A, 2 filings Feb 10, 2023 to Jan 23, 2024⁵⁷
• ORBIMED ADVISORS LLCSC 13D/A, 4 filings Sep 14, 2022 to Dec 6, 2023⁵⁸
• BC SW, LPSC 13D/A, 2 filings Sep 13, 2022 to Mar 20, 2023⁵⁹
• PERCEPTIVE ADVISORS LLCSC 13G/A, 2 filings Feb 15, 2022 to Feb 14, 2023⁶⁰
• Boxer Capital, LLCSC 13G, 1 filing Sep 19, 2022⁶¹
• PfizerSC 13G/A, 1 filing Feb 14, 2022⁶²

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How SpringWorks Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARSpringWorks Therapeutics, Inc.¹
• CIK0001773427
• Employer ID (EIN)83-4066827³
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address100 Washington Boulevard, Stamford, CT 06902¹
• Phone203-883-9490¹
• Shares outstanding75,322,696 as of May 2, 2025¹¹
• Public float$2.7B as of Jun 30, 2024³
• AuditorErnst & Young LLP, Hartford, Connecticut PCAOB ID 42; it also attests to the company’s internal control over financial reporting³
• On EDGAR sinceApr 12, 2019¹
• Filings461 in all: 4 (208), 8-K (57), 3 (25), SC 13G/A (19), 144 (18), 10-Q (17), SC 13D/A (11), SC 13G (10)¹
  All 41 form types

  DEFA14A (9), 4/A (7), CORRESP (7), S-8 (7), S-8 POS (7), 10-K (6), 424B5 (6), DEF 14A (6), UPLOAD (6), SCHEDULE 13G/A (4), ARS (3), SCHEDULE 13G (3), S-1/A (2), S-3ASR (2), SC 13D (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 5 (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), POSASR (1), PREM14A (1), S-1 (1)

• Latest filingsAnnual report (10-K) Feb 20, 2025
  Quarterly report (10-Q) May 9, 2025
  Proxy statement (DEF 14A) Apr 4, 2025
  Latest 8-K (8-K) Jul 1, 2025

Securities registered for trading

From the cover page of the 10-K filed Feb 20, 2025 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks SpringWorks Therapeutics, Inc. names in Item 1A of its 10-K filed Feb 20, 2025: 70 risks under these headings, as written.³

• •Our business depends heavily on our ability to successfully commercialize OGSIVEO and GOMEKLI in the United States and in other jurisdictions where we may obtain marketing approval, including Europe. There is no assurance that our commercialization efforts with respect to OGSIVEO or GOMEKLI will be successful or that we will be able to generate revenues at the levels or on the timing we expect, or at levels or on the timing necessary to support our goals.
• •We have limited experience as a commercial company and the sales, marketing, and distribution of OGSIVEO, GOMEKLI, or any future approved products may be unsuccessful or less successful than anticipated.
• •Our business is highly dependent on the successful commercialization of OGSIVEO and GOMEKLI and development of our current product candidates. If we are unable to successfully commercialize OGSIVEO or GOMEKLI or successfully complete clinical development of, obtain regulatory approval for, or commercialize, our product candidates, or if we experience delays in doing so, our business will be materially harmed.
• •We were not involved in the early development of our lead products or in the development of third-party agents being developed in combination with our product candidates; therefore, we are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical and clinical trials for our products and product candidates.
• •If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.
• •Interim “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available, are not necessarily predictive of the final results of the completed study or the results of other ongoing or future studies and are subject to audit and verification procedures that could result in material changes.
• •We expect to develop nirogacestat and mirdametinib, and potentially future product candidates, in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of such product candidates.
• •If we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• •The target patient populations of OGSIVEO for the treatment of desmoid tumors and GOMEKLI for the treatment of NF1-PN are small and have not been definitively determined, and if our estimates of the number of treatable patients is lower than expected, our potential revenues from sales of OGSIVEO or of GOMEKLI and our ability to achieve profitability would be compromised.
• •Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payers, or others in the medical community necessary for commercial success.
• •We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.
• •Because we rely on third-party manufacturing and supply partners, our supply of preclinical and clinical development materials and commercial product may become limited or interrupted or may not be of satisfactory quantity or quality, which could delay, prevent or impair our development or commercialization efforts.

Legal proceedings

We are not currently a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.³